INTRODUCTION
Parainfluenza virus type 3 (PIV3) is a member of the Paramyxoviridae (Kingsbury et al., 1978) . It causes respiratory infections of humans which can be serious in infants but generally are mild in adults (Wenzel et al., 1972) . Immunity to PIV3 is shortlived and re-infections are frequent (Glezen et al., 1982; Muchmore et al., 1981) . In lambs, protection against disease with a related type of virus is mediated by an immune response to the haemagglutinin-neuraminidase (HN) and fusion (F) surface glycoproteins (Morein et al., 1983) . Immunity to both of these envelope proteins seems to be important in diseases caused by paramyxoviruses (Norrby et al., 1975) . Immunization with solubilized human PIV3 HN and F glycoproteins has been shown to protect hamsters from challenge infection whereas formalin-inactivated whole virus did not protect (Ray et al., 1985) . Tween 80-ether-and formalin-inactivated measles vaccines also proved not to give satisfactory protection, possibly because fusion-inhibiting antibodies against the F protein were not induced (Norrby et al., 1975) . The result, in some cases, was a serious atypical disease in the vaccinees upon exposure to measles virus (Fulginiti et al., 1967) . Also, monoclonal antibodies (MAbs) directed against the HA protein of measles virus can alter the course of measles encephalitis in mice from an acute lethal to a late subacute disease (Rammohan et al., 1981) .
Paramyxoviruses, when inoculated intracerebrally, can cause encephalitis in rodents (Rammohan et al., 1981 ; Shibuta et al., 1985; Wolinsky et al., 1985) . These models have been very useful for the study of virus-neuron interactions and host responses, and for evaluation of pathogenetic determinants of virus strains (L6ve et al., 1985 a, b, 1986 a, b) . In the present study PIV3 was adapted to newborn hamsters, in which it caused a highly lethal brain infection. With the aid of this model, a collection of MAbs against the HN and F proteins of PIV3 was used for passive immunization in order to determine the importance of immunity to epitopes on individual surface glycoproteins.
METHODS

Preparation of virus.
The American Type Culture Collection strain C243 of PIV3 was used for all infections. This strain was isolated in 1958 from a human case of respiratory infection (Chanock et al., 1958) and had been passaged about 10 times in Vero cells in this laboratory before use. Stock virus was grown in Veto ceUs using Eagle's minimal essential medium (Flow Laboratories) supplemented with 5~ foetal calf serum and antibiotics. 
Injection of animals with virus and antibody.
For animal infections, locally bred newborn (< 24 h old) golden Syrian hamsters were used. The encephalogenicity of the virus strain was increased by three serial intracerebral passages in newborn hamsters. Subsequently it was plaque-purified three times and the encephalitogenic capacity of the virus was tested. The titre of the virus used for inoculations was 7 x t05 p.f.u./ml. All animals were infected intracerebrally in the midline with a tuberculin syringe and 0.4 mm diameter needle. The amount of inoculum was 0.02 ml. Simultaneously, the animals were injected subcutaneously with 0.03 ml of MAb-containing ascites. The MAbs used have been characterized earlier (Rydbeck et al., , 1987 and covered all previously identified epitope groups.
Titration of viral activity. The infected animals were inspected daily and survival curves were plotted. Animals that died during the first 2 days after inoculation were considered to have succumbed as a result of the injection procedure and were therefore excluded from the study. For titration of viral activity in infected brains, randomly picked animals were sacrificed every second day, and the brains were homogenized in a mortar and diluted to a 10~ (w/v) suspension in phosphate-buffered saline, pH 7-2. Subsequently the viral activity was titrated by a plaque assay as previously described (Rydbeck et al., 1987) .
RESULTS
The results of passive immunization with MAbs against the HN protein are shown in Fig. 1  and 2 . The survival curves demonstrate variable degrees of protection. MAbs against epitope groups I, V and VI were shown to provide minimal or no protection against lethal disease. There was no statistically significant difference, in a paired t-test, between the survival of treated and untreated animals, nor was there any significant difference between the curves representing lower survival than the control animals and the control curve. Some protection was demonstrated with MAbs against groups II, III and IV; all three survival curves were statistically different (P = 0.01) in paired t-tests from the untreated control curve. The survival time of animals was lengthened and viral titres were reduced in the brains (Fig. 3) . The difference between the viral titre curves of animals treated with MAbs 3285, 4673 and 4702 and untreated animals were statistically significant in paired t-tests at a level ofP = 0-001. At 8 days p.i., however, the differences were not significant. Animals immunized with MAbs conferring some degree of protection generally died as a result of hydrocephalus. Interestingly MAb 106, against the HN protein of Sendal virus (murine parainfluenza virus type 1) (Orvell & Grandien, 1982) , also protected (P = 0.01) against PIV3 brain infection (Fig. 4) . This antibody has been shown to cross-react with PIV3 and was shown to possess low haemagglutination inhibition (HI) capacity and high neutralization activity (Table 1 ). The epitope represented by this antibody was designated HNs. The results from the passive immunization with MAbs against the F protein are shown in Fig.  3 and 5. Only MAb 4673 conferred protection, seen both as a longer survival time of animals and a reduction of viral titres in the brain. A combination (0.03 ml) of anti-F MAb 4789 and anti-HN MAb 3285 did not increase the protective effects of MAb 3285 (data not shown), and animals treated with anti-PIV3 nucleocapsid (NP) protein antibody 4861 did not differ significantly from untreated animals (Fig. 4) .
DISCUSSION
This study has shown that the different MAbs against the HN and F proteins of PIV3 have a variable capacity to protect against lethal brain infections. These results are similar to those of previous studies on Sendai virus and mumps virus infections. (L6ve et al., 1985b , 1986b Orvell & Grandien, 1982; Wolinsky et al., 1985) . No MAb against PIV3 protected totally against lethal disease, but the MAbs against the HN protein exhibiting the highest neutralization capacity in vitro showed the best protective effects. MAb 4673, against the F protein, with low in vitro neutralization capacity , conferred protection and reduced viral titres in vivo. No protection was demonstrated with non-neutralizing antibodies against either of the two envelope proteins of PIV3. This situation differs from that of mumps virus (L6ve et al., 1986b (L6ve et al., ), vesicular stomatitis virus (Lefrancois, 1984 and Sindbis virus (Schmaljohn et al., 1982) where non-neutralizing MAbs can confer protection against disease. In the case of mumps virus, nonneutralizing MAbs against the F protein were found to drastically reduce cytopathology in the brain and thereby protect against disease.
The results presented here are in accordance with those of Orvell & Grandien (1982) who found no correlation between HI, haemolysis inhibition (HLI) and neutralization (NT) activities of anti-Sendai virus HN and F MAbs and passive protection by reduction of virus titres in the lungs of mice. Similar results were observed in an in vitro system using MAbs to inhibit mumps virus-dependent cellular cytotoxicity (VDCC) (Alsheikhly et al., 1985) . This emphasizes the importance of certain antibody-binding sites (see Yewdell & Gerhard, 1982) although other characteristics, such as the Fc fragment and affinity, may also be important for protection against disease. However, Table 1 and Fig. 2 show that even though the antibody class, subclass and in vitro titres of MAbs 4678 and 4830 are similar, there is a difference in vivo in biological activity; further, in the report by Alsheikhly et al. (1985) there was no correlation between MAb-mediated inhibition of VDCC and their apparent association constants. A further evaluation of combinations of MAbs would be of interest, since it has been found that antibodies may enhance each other's neutralizing effects (Dimmock, 1984; Russell, 1986) .
It is noteworthy that a MAb against Sendai virus protected against PIV3 infection. The neutralizing epitope represented by MAb 106 can be placed in epitope group II of Orvell & Grandien (1982) on the basis of low HI and high HLI activities. The epitope was further differentiated by 0rvell et al. (1986) when it was found to be present on the HN proteins of both Sendai virus and PIV3 while two MAbs of the same group (II) were shown to react with Sendai virus only. This confirms the close relationship between the two viruses (0rvell et al., 1986) and suggests stability of this common epitope during evolution. The significance of this in human infections is unknown, but in systemic disease measles virus and rinderpest virus-vaccinated dogs have been protected against canine distemper virus (Appel & Gillespie, 1972) .
